Treatment philosophies in multiple myeloma (MM) debate the relative merits of achieving deepest possible remissions ("curative" doctrine) versus sequential delivery of anti-myeloma agents ("control" doctrine). In this Spotlight, we highlight the relevant strengths of each doctrine in the context of modern patient selection strategies, fresh biologic insights on MM pathogenesis, agents with improved safety profiles, and emerging molecular and imaging tools. Paramount fundamental questions remain unanswered that require intense research focus as we pursue a cure of this devastating disease.
- Submitted January 28, 2013.
- Accepted June 16, 2013.
- Copyright © 2005 American Society of Hematology